Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Comparison of Two Vitamin D3 Doses (500,000 IU vs 750,000 IU) in Critically Ill Patients with Vitamin D Deficiency Receiving Continuous Renal Replacement Therapy

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study focuses on patients with severe Vitamin D3 deficiency who are critically ill and receiving continuous renal replacement therapy (a treatment that helps filter waste from the blood when the kidneys are not working properly). The study compares two different doses of vitamin D3 (also known as colecalciferol) given as oral drops through a feeding tube or by mouth to these patients.

The purpose of this research is to determine how effectively two different doses of vitamin D3 (500,000 IU and 750,000 IU) can increase vitamin D levels in the blood. The medication being used is Devikap, which comes as an oral solution in the form of drops. Patients will receive a single dose of the medication and will be monitored for several days afterward.

During the study, doctors will check vitamin D levels in the blood and monitor various aspects of patient health. The study will track how patients respond to the treatment, including their recovery progress and any changes in their condition. This research is particularly important for critically ill patients who often have very low vitamin D levels while receiving kidney support treatment.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial vitamin D3 level measurement

    Your blood will be tested to measure vitamin D3 levels. This test will be performed at the hospital laboratory.

    You must have a vitamin D3 level of 12.5 ng/ml or lower to continue in the study.

  2. Step 2

    Vitamin D3 administration

    You will receive a single dose of vitamin D3 (Devikap) through a feeding tube or by mouth.

    The dose will be either 500,000 IU or 750,000 IU of vitamin D3 oral drops solution.

  3. Step 3

    Day 3 follow-up

    Blood tests will be performed to check your vitamin D3 levels

    Your blood calcium levels will be monitored

    Your organ function will be assessed using a special scoring system (SOFA score)

  4. Step 4

    Day 7 follow-up

    Additional blood tests will check your vitamin D3 levels

    Your blood calcium levels will be monitored again

    Your organ function will be reassessed (SOFA score)

  5. Step 5

    Day 28 assessment

    Your health status will be evaluated

    The duration of your intensive care unit stay will be recorded

    The length of time you needed special kidney treatment (continuous renal replacement therapy) will be documented

  6. Step 6

    Final assessment - Day 90

    Final health status evaluation will be performed

    This marks the end of your participation in the study

Who can join the trial?

11 criteria

  • Must be at least 18 years old
  • Must have a severe vitamin D3 deficiency with blood levels of 25(OH)D3 equal to or below 12.5 ng/ml, confirmed by hospital laboratory tests
  • Must be receiving continuous renal replacement therapy (a treatment that helps filter blood when kidneys are not working properly) due to at least one of these conditions:
    • Acute kidney injury
    • High potassium levels in blood
    • Severe acid levels in blood
    • Fluid in lungs
    • Uremia complications (bleeding problems or heart sac inflammation)
    • Excess fluid in body
    • Must have a SOFA score (a measure of organ failure) of at least 5 when entering the study
    • Must be able to receive nutrition through a feeding tube or by mouth at any amount
    • Can be either male or female

Who cannot join the trial?

13 criteria

  • Age below 18 years or above 75 years
  • Known hypersensitivity (allergic reaction) to vitamin D3 or any components of the supplement
  • Pregnant or breastfeeding women
  • Patients with hypercalcemia (high levels of calcium in the blood)
  • Patients with severe liver disease
  • Patients not receiving continuous renal replacement therapy (a type of dialysis treatment)
  • Patients unable to receive medication through a feeding tube or by mouth
  • Patients with active tuberculosis (TB infection)
  • Patients taking medications that could interact with vitamin D3 metabolism
  • Patients participating in other clinical trials
  • Patients with disorders affecting vitamin D absorption
  • Patients who received high-dose vitamin D supplementation in the past 3 months
  • Patients with sarcoidosis (an inflammatory disease affecting multiple organs)
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Vitamin D3 (cholecalciferol) is a vital nutrient that helps your body absorb calcium and maintain strong bones. In this trial, it is given to critically ill patients who are receiving kidney dialysis treatment. The vitamin is administered through a feeding tube or taken by mouth. This supplementation is particularly important for patients with severe vitamin D3 deficiency who are in intensive care and undergoing continuous kidney treatment.

What is already known about the treatment

Vitamin D3 (Cholecalciferol) - A fat-soluble vitamin administered orally or through a gastric tube, particularly important in critically ill patients with severe deficiency undergoing continuous renal replacement therapy. This essential nutrient plays a crucial role in calcium absorption, bone health, and immune system function, with its active form (25-hydroxyvitamin D3) being monitored in blood serum levels. In clinical settings, high-dose supplementation (ranging from 500,000 to 750,000 IU) is being studied for treating severe deficiency states in intensive care patients, representing a significant therapeutic intervention compared to standard supplementation doses.

Investigated diseases

Vitamin D3 Deficiency - A condition that occurs when the body has insufficient levels of vitamin D3, an essential nutrient needed for bone health and other bodily functions. The body typically gets vitamin D3 through sunlight exposure, certain foods, or supplements. When levels become too low, it can affect how the body absorbs and uses calcium and phosphorus. This deficiency can develop gradually and may be more common in people who have limited sun exposure, darker skin, or certain medical conditions. In severe cases, particularly in intensive care settings, the deficiency can become significantly pronounced due to various factors including reduced sun exposure and medical treatments like continuous renal replacement therapy.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-510834-42-00Protocol codeNephroD_2021Estimated enrolment138 patientsSponsorUniwersytecki Szpital Kliniczny W Opolu

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.